| [1] PubMed ID: | 35404176 |
| Disease Name: | Rhinitis, Allergic |
| Sample: | AR cell model |
| Dysfunction Pattern: | Interaction(miR-16-5p/TLR4 Axis) |
| Validated Method: | qRT-PCR//Luciferase Report Assay//RIP//Western Blot |
| Description: | Moreover, knockdown of ANRIL reversed the effect of AR on autophagy-related protein and tight junction proteins MiR-16-5p was found to be bound with ANRIL and miR-16-5p inhibitor could reverse ANRIL knockdown-induced downregulation of autophagy-related proteins and epithelial barrier dysfunction. In addition, miR-16-5p directly targeted TLR4. Furthermore, knockdown of ANRIL reversed miR-16-5p and TLR4 expression, autophagy level, and tight junction protein levels in nasal mucosa of AR mice. |
| Causality: | Yes |
| Causal Description: | Moreover, knockdown of ANRIL reversed the effect of AR on autophagy-related protein and tight junction proteins MiR-16-5p was found to be bound with ANRIL and miR-16-5p inhibitor could reverse ANRIL knockdown-induced downregulation of autophagy-related proteins and epithelial barrier dysfunction. In addition, miR-16-5p directly targeted TLR4. Furthermore, knockdown of ANRIL reversed miR-16-5p and TLR4 expression, autophagy level, and tight junction protein levels in nasal mucosa of AR mice. |
| Clinical-realted Application: | |
| [2] PubMed ID: | 31096432 |
| Disease Name: | Rhinitis, Allergic |
| Sample: | nasal mucosa tissue |
| Dysfunction Pattern: | Expression[highly expressed] |
| Validated Method: | qRT-PCR |
| Description: | LncRNA ANRIL expression was increased in AR patients (3.605 [1.763-4.981]) compared with controls (1.183 [0.438-2.985]), |
| Causality: | No |
| Causal Description: | |
| Clinical-realted Application: | |
|